Increased risk of CVD after VT is determined by common etiologic factors

Blood

Volumn 121, Issue 24, 2013, Pages 4948-4954

  Roach, Rachel E J ^a   Lijfering, Willem M ^a   Flinterman, Linda E ^a   Rosendaal, Frits R ^a   Cannegieter, Suzanne C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; C REACTIVE PROTEIN; FIBRINOGEN; PROTHROMBIN;

ADULT; AGE; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLOOD GROUP; BODY MASS; CARDIOVASCULAR RISK; CHRONIC DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; INCIDENCE; LIFESTYLE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOM DIGIT DIALING; SENSITIVITY ANALYSIS; SEX; SMOKING; THROMBOPHILIA; ADOLESCENT; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CONTROLLED CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; TIME; VEIN THROMBOSIS;

ADOLESCENT; ADULT; AGED; BRAIN ISCHEMIA; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RETROSPECTIVE STUDIES; STROKE; TIME FACTORS; VENOUS THROMBOSIS;

MLCS; MLOWN;

EID: 84881302693     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-01-479238     Document Type: Article

References (37)

1. Fauci AS, Braunwald E, Kasper DL, et al. Harrison’s Principles of Internal Medicine. New York, NY: McGraw-Hill; 2008
2. Prandoni P, Bilora F, Marchiori A, et al. An association between atherosclerosis and venous thrombosis. N Engl J Med. 2003;348(15): 1435-1441.
3. Sørensen HT, Horvath-Puho E, Pedersen L, Baron JA, Prandoni P. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet. 2007;370(9601):1773-1779.
4. Klok FA, Mos IC, Broek L, Tamsma JT, Rosendaal FR, de Roos A, Huisman MV. Risk of arterial cardiovascular events in patients after pulmonary embolism. Blood. 2009;114(8): 1484-1488.
5. Becattini C, Vedovati MC, Ageno W, Dentali F, Agnelli G. Incidence of arterial cardiovascular events after venous thromboembolism: a systematic review and a meta-analysis. J Thromb Haemost. 2010;8(5):891-897.
6. Lijfering WM, Flinterman LE, Vandenbroucke JP, Rosendaal FR, Cannegieter SC. Relationship between venous and arterial thrombosis: a review of the literature from a causal perspective. Semin Thromb Hemost. 2011;37(8):885-896.
7. Reich LM, Folsom AR, Key NS, Boland LL, Heckbert SR, Rosamond WD, Cushman M. Prospective study of subclinical atherosclerosis as a risk factor for venous thromboembolism. J Thromb Haemost. 2006;4(9):1909-1913.
8. van der Hagen PB, Folsom AR, Jenny NS, et al. Subclinical atherosclerosis and the risk of future venous thrombosis in the Cardiovascular Health Study. J Thromb Haemost. 2006;4(9):1903-1908.
9. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T; ATAC Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359(9324): 2131-2139.
10. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol. 1991;9(2):286-294.
11. van Schouwenburg IM, Gansevoort RT, Mahmoodi BK, et al. Increased risk of arterial thromboembolism after a prior episode of venous thromboembolism: results from the Prevention of REnal and Vascular ENd stage Disease (PREVEND) study. Br J Haematol. 2012;159(2): 216-222.
12. Cooper R, Cutler J, Desvigne-Nickens P, et al. Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the national conference on cardiovascular disease prevention. Circulation. 2000;102(25):3137-3147.
13. Yusuf S, Hawken S, Ounpuu S, et al; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937-952.
14. Zöller B, Li X, Sundquist J, Sundquist K. Socioeconomic and occupational risk factors for venous thromboembolism in Sweden: A nationwide epidemiological study. Thromb Res. 2012;129(5):577–582.
15. Pomp ER, Rosendaal FR, Doggen CJ. Alcohol consumption is associated with a decreased risk of venous thrombosis. Thromb Haemost. 2008; 99(1):59-63.
16. Wacholder S, Silverman DT, McLaughlin JK, Mandel JS. Selection of controls in case-control studies. II. Types of controls. Am J Epidemiol. 1992;135(9):1029-1041.
17. van Stralen KJ, Rosendaal FR, Doggen CJ. Minor injuries as a risk factor for venous thrombosis. Arch Intern Med. 2008;168(1):21-26.
18. Pomp ER, Rosendaal FR, Doggen CJ. Smoking increases the risk of venous thrombosis and acts synergistically with oral contraceptive use. Am J Hematol. 2008;83(2):97-102.
19. Bezemer ID, van der Meer FJ, Eikenboom JC, Rosendaal FR, Doggen CJ. The value of family history as a risk indicator for venous thrombosis. Arch Intern Med. 2009;169(6):610-615.
20. Bezemer ID, Bare LA, Doggen CJ, et al. Gene variants associated with deep vein thrombosis. JAMA. 2008;299(11):1306-1314.
21. Kuipers S, Cannegieter SC, Doggen CJ, Rosendaal FR. Effect of elevated levels of coagulation factors on the risk of venous thrombosis in long-distance travelers. Blood. 2009;113(9):2064-2069.
22. Meltzer ME, Lisman T, Doggen CJ, de Groot PG, Rosendaal FR. Synergistic effects of hypofibrinolysis and genetic and acquired risk factors on the risk of a first venous thrombosis. PLoS Med. 2008;5(5):e97.
23. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6): 715-722.
24. Flinterman LE, van Hylckama Vlieg A, Cannegieter SC, Rosendaal FR. Long-term survival in a large cohort of patients with venous thrombosis: incidence and predictors. PLoS Med. 2012;9(1):e1001155.
25. De Bruin A, Kardaun JW, Gast F, de Bruin E, van Sijl M, Verweij G. Record linkage of hospital discharge register with population register: experiences at Statistics Netherlands. Stat J United Nations Econ Commission Eur. 2004;21: 23–32.
26. Stricker BH, Herings RM. [Plea for the retention of the Dutch National Medical Registration (LMR) to provide reliable information regarding public health and healthcare]. Ned Tijdschr Geneeskd. 2006;150(35):1916-1917.
27. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ; American College of Chest Physicians. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):454S-545S.
28. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council’s General Practice Research Framework. Lancet. 1998;351(9098): 233-241.
29. Fuster V, Rydén LE, Cannom DS, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114(7):e257-e354.
30. Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. New York, NY: Springer; 2000
31. Holst AG, Jensen G, Prescott E. Risk factors for venous thromboembolism: results from the Copenhagen City Heart Study. Circulation. 2010; 121(17):1896-1903.
32. Veeger NJ, Piersma-Wichers M, Tijssen JG, Hillege HL, van der Meer J. Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism. Br J Haematol. 2005;128(4):513-519.
33. Tichelaar V, Mulder A, Kluin-Nelemans H, Meijer K. The acute phase reaction explains only a part of initially elevated factor VIII:C levels: a prospective cohort study in patients with venous thrombosis. Thromb Res. 2012;129(2):183-186.
34. Kamphuisen PW, Eikenboom JC, Vos HL, Pablo R, Sturk A, Bertina RM, Rosendaal FR. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost. 1999;81(5):680-683.
35. Kraaijenhagen RA, in’t Anker PS, Koopman MM, et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost. 2000;83(1):5-9.
36. Becattini C, Agnelli G, Schenone A, et al; WARFASA Investigators. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med. 2012;366(21):1959-1967.
37. Brighton TA, Eikelboom JW, Mann K, et al; ASPIRE Investigators. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med. 2012;367(21):1979-1987.